Skip to main content
  • English
  • Français
  • Español
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. SCFAs: new intestinal markers of Parkinson’s disease?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. SCFAs: new intestinal markers of Parkinson’s disease?
Gastroenterology

SCFAs: new intestinal markers of Parkinson’s disease?

Parkinson's disease
Gastroenterology Neurology

Short-chain fatty acids (SCFAs) are gut microbiota metabolites already known to be involved in Parkinson’s disease, particularly in rodents. But what about in humans?

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 22 April 2022
Updated 02 May 2022

(sidenote: https://parkinsonscare.org.uk/worldparkinsonsday/ ) (April 11) is an opportunity each year for patient associations and health professionals to see how research is progressing on this complex neurodegenerative disease for which there is no treatment to date. This year, discussions will no doubt focus on a new study by a team of Taiwanese researchers. The team wanted to determine whether SCFAs could discriminate between Parkinson’s patients and healthy individuals, and whether there was a correlation with disease severity. To do this, they analyzed plasma and fecal levels of several subtypes of SCFAs in addition to the gut microbiota of 181 participants (96 patients and 85 controls). They also studied the motor and cognitive effects of the disease. The study results were published in Neurology in early 2022.

Different fecal and plasma SCFA levels in Parkinson’s patients 

In Parkinson’s patients, the results showed reduced fecal SCFA levels compared to healthy individuals (butyric acid, valeric acid and propionic acid), whereas plasma levels were higher. 
Another takeaway: fecal quantities of the same SCFAs were lower in patients with advanced Parkinson’s disease compared to patients in the early stages of the disease.

Correlation between SCFA levels and symptom severity 

Fecal and plasma concentrations vary depending on the severity of motor and cognitive symptoms. 

More severe motor impairment is correlated with a low fecal concentration of most SCFAs, coupled with an increased plasma propionic acid concentration.

More serious cognitive symptoms are associated with lower fecal levels of butyric acid and higher plasma concentrations of butyric acid and valeric acid.

Link between the composition of patient microbiota and SCFAs

The study showed that microbial diversity in Parkinson’s patients differed from that in healthy patients. This study highlights the correlation between SCFA concentrations and the abundance of pro-inflammatory bacteria (Clostridiales and Ruminococcus), particularly in the case of propionic acid. This supports the hypothesis that gut inflammation is associated positively with disease aggravation.

Specifically, these results suggest that SCFAs may serve as gut biomarkers for Parkinson’s disease and also reflect severity. This is an interesting scientific advance, which may pave the way for more accurate diagnosis and better patient management.

Sources

Chen SJ, Chen CC, Liao HY, et al. ; Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. Neurology. 2022 Feb 22;98(8):e848-e858.

Tags
Parkinson SCFA Gut-brain axis

en_view en_sources

    See also

    Actu PRO : Maladie de parkinson : les antibiotiques, et le microbiote, impliqués Role of antibiotics and microbiota in parkinson's disease
    Photo : The gut microbiome and neurodegeneration The gut microbiome and neurodegeneration
    Created 22 April 2022
    Updated 02 May 2022

    About this article

    To know more about this topic.

    Main topic

    Parkinson's disease

    Medical practice

    Gastroenterology Neurology

    Content type

    News
    Gastroenterology

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Microbiota in covid-19 pandemic

    Overview By Pr. Conceição Calhau NOVA Medical School, New University of Lisbon, Portugal By Pr. Pedro Povo...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Continue reading

    News
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    15.04.2022

    Multiple sclerosis and microbiota: does meat consumption play a role?

    Read the article
    08.04.2022

    Inflammatory Bowel Disease (IBD): do microplastics condition severity?

    Read the article
    04.04.2022

    The microbiota, a significant factor in smoking cessation

    Read the article
    30.04.2019

    The lingual microbiota, biomarker of pancreatic cancer?

    Read the article
    15.06.2021

    Autism: link between severity of the disorder and changes in the gut microbiota?

    Read the article
    Actu PRO : A chaque tumeur son microbiote
    20.11.2020

    Each tumor has its own microbiota

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    en_redirection

    en_you_are_about_to_leave

    • en_be_redirected
    • en_stay_on_biocodex

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo